Evidence map›Paper›PMID 41755723›Full record

ArticleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2026

Two cases of possible transmitted HIV drug resistance to all currently available integrase inhibitors, the Netherlands, 2025.

Jeroen van Kampen, Jolanda Voermans, Widia Soochit, Thibault Mesplède, Thijs van de Laar, Wil van der Reijden, David Burger, Noga Shalev, Ard van Sighem, Daniela Bezemer and 4 more

Abstract readCase Reports
In one paragraph

Article in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Letter to the editor: When do rare events become expected in HIV drug resistance?Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Jeroen van KampenDepartment of Viroscience, Erasmus University Medical Center, Rotterdam, the Netherlands.
Jolanda VoermansDepartment of Viroscience, Erasmus University Medical Center, Rotterdam, the Netherlands.
Widia SoochitDepartment of Medical Microbiology and infectious Diseases, Erasmus University Medical Center, Rotterdam, the Netherlands.
Thibault MesplèdeDepartment of Viroscience, Erasmus University Medical Center, Rotterdam, the Netherlands.
Thijs van de LaarLaboratory of blood-borne infections, Sanquin Research, Amsterdam, the Netherlands.
Wil van der ReijdenDepartment of Medical Microbiology, OLVG Lab, Amsterdam, the Netherlands.
David BurgerDepartment of Pharmacy, Pharmacology & Toxicology, Radboud University Medical Center, Nijmegen, the Netherlands.
Noga ShalevStichting hiv Monitoring, Amsterdam, the Netherlands.
Ard van SighemStichting hiv Monitoring, Amsterdam, the Netherlands.
Daniela BezemerStichting hiv Monitoring, Amsterdam, the Netherlands.
Suzanne JurriaansDepartment of infectious diseases, and Amsterdam Institute for Immunology and Infectious Diseases (AII), Amsterdam UMC location University of Amsterdam, Amsterdam, the Netherlands.
Thomas van der VaartDepartment of infectious diseases, and Amsterdam Institute for Immunology and Infectious Diseases (AII), Amsterdam UMC location University of Amsterdam, Amsterdam, the Netherlands.
Hanna de JongDepartment of infectious diseases, and Amsterdam Institute for Immunology and Infectious Diseases (AII), Amsterdam UMC location University of Amsterdam, Amsterdam, the Netherlands.
Marc van der ValkStichting hiv Monitoring, Amsterdam, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Transmitted integrase inhibitor resistance in newly diagnosed HIV remains rare. We report two cases with baseline resistance to all currently available integrase inhibitors in the Netherlands in 2025. Clinical history and laboratory findings indicate possible transmitted resistance. The cases are not phylogenetically linked, representing two independent introductions of integrase inhibitor resistant HIV into the Dutch population. These observations highlight the need for strengthened surveillance and prevention efforts in Europe and globally.

Indexed as

Drug Resistance, ViralHIV-1HIV InfectionsHIV Integrase InhibitorsAdultDolutegravirHeterocyclic Compounds, 3-RingHumansMaleNetherlandsOxazinesPiperazinesPyridonesDolutegravirHeterocyclic Compounds, 3-RingHIV Integrase InhibitorsOxazinesPiperazinesPyridonesbictegravircabotegravirdolutegravirHIVINSTItransmitted drug resistance

Identifiers

PMID41755723
PMCPMC13074222

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.